Ypsomed Holding AG
SIX:YPSN

Watchlist Manager
Ypsomed Holding AG Logo
Ypsomed Holding AG
SIX:YPSN
Watchlist
Price: 357 CHF 2.59% Market Closed
Market Cap: 4.9B CHF
Have any thoughts about
Ypsomed Holding AG?
Write Note

Net Margin
Ypsomed Holding AG

12.1%
Current
9%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
74.4m
/
Revenue
617.1m

Net Margin Across Competitors

Country CH
Market Cap 4.9B CHF
Net Margin
12%
Country JP
Market Cap 6.8T JPY
Net Margin
24%
Country CH
Market Cap 37.9B CHF
Net Margin
12%
Country DK
Market Cap 200.9B DKK
Net Margin
19%
Country US
Market Cap 16.9B USD
Net Margin
11%
Country KR
Market Cap 9.9T KRW
Net Margin
-358%
Country CA
Market Cap 6.9B USD
Net Margin
-8%
Country CN
Market Cap 48.6B CNY
Net Margin
42%
Country US
Market Cap 6.3B USD
Net Margin
29%
Country US
Market Cap 6.1B USD
Net Margin
9%
Country UK
Market Cap 4.8B GBP
Net Margin
7%
No Stocks Found

Ypsomed Holding AG
Glance View

Market Cap
4.9B CHF
Industry
Health Care

Ypsomed Holding AG is a Swiss-based medical technology company that has carved out a niche in the rapidly growing diabetes management and drug delivery market. Founded in 1984, the company initially focused on producing insulin delivery systems but has since expanded its portfolio to include sophisticated pens and pumps that facilitate self-administration of medications. With an emphasis on innovation and user-centered design, Ypsomed has positioned itself as a leader in the development of advanced delivery systems that cater to the evolving needs of patients and healthcare providers alike. The company’s strategic partnerships with pharmaceutical firms enhance its growth trajectory, underscoring its commitment to improving patient outcomes and fostering adherence to treatment regimens. As an investor, you’ll appreciate Ypsomed’s robust financial performance, characterized by consistent revenue growth and a solid balance sheet. The company not only serves a significant portion of the diabetic population but also capitalizes on the increasing demand for self-medication and chronic disease management solutions. With a keen focus on research and development, Ypsomed is well-prepared to leverage trends in digital health and personalized medicine. Its global market presence, combined with a dedication to sustainability and innovation, positions Ypsomed as a compelling investment opportunity in a healthcare sector that is both resilient and essential. Ultimately, Ypsomed's commitment to transforming healthcare through advanced technology makes it an appealing choice for investors looking to tap into the future of medical devices.

YPSN Intrinsic Value
434.69 CHF
Undervaluation 18%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.1%
=
Net Income
74.4m
/
Revenue
617.1m
What is the Net Margin of Ypsomed Holding AG?

Based on Ypsomed Holding AG's most recent financial statements, the company has Net Margin of 12.1%.